| Ημερομηνία | barcode | code | περιεχομενο | τιμή παραγωγός | χονδρική | λιανική |
|---|---|---|---|---|---|---|
| 05/2018 | 2802809102026 | 280910202 | MARIPRAX TAB 0,18MG/TAB BTx100 (Blister 10x10), (PA/Alu/PVC/Alu) (Blister 10x10), (PA/Alu/PVC/Alu) | 7.56 | 7.93 | 10.93 |
| 05/2018 | 2802809103023 | 280910302 | MARIPRAX TAB 0,7MG/TAB BTx100 (Blister 10x10), (PA/Alu/PVC/Alu) (Blister 10x10), (PA/Alu/PVC/Alu) | 30.03 | 31.50 | 43.41 |
For the treatment of signs and symptoms of idiopathic Parkinson's disease
The precise mechanism of action of Pramipexole as a treatment for Parkinson's disease is unknown, although it is believed to be related to its ability to stimulate dopamine receptors in the striatum.
Rapid. Absolute bioavailability is greater than 90%, indicating that pramipexole is well absorbed and undergoes little presystemic metabolism. Food does not affect the extent of absorption.
8 hours
Urinary excretion is the major route of pramipexole elimination, with 90% of a pramipexole dose recovered in urine, almost all as unchanged drug. Nonrenal routes may contribute to a small extent to pramipexole elimination, although no metabolites have been identified in plasma or urine.
* 500 L
* renal cl=400 mL/min